Exablate Model 4000 for Neoplasms, Brain

Phase-Based Progress Estimates
University of Maryland, Baltimore & The University of Maryland Medical System, Baltimore, MD
Neoplasms, Brain+2 More
Exablate Model 4000 - Device
All Sexes
What conditions do you have?

Study Summary

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with Glioblastoma brain tumors

Eligible Conditions

  • Neoplasms, Brain

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Neoplasms, Brain

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: Through study completion, up to 1 year

1 hour post BBBD
Circulating Free DNA
Correlation with Tumor Tissue
Year 1
Adverse Events

Trial Safety

Safety Progress

1 of 3

Other trials for Neoplasms, Brain

Trial Design

1 Treatment Group

Exablate BBBD
1 of 1
Experimental Treatment

57 Total Participants · 1 Treatment Group

Primary Treatment: Exablate Model 4000 · No Placebo Group · N/A

Exablate BBBD
Experimental Group · 1 Intervention: Exablate Model 4000 · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, up to 1 year
Closest Location: University of Maryland, Baltimore & The University of Maryland Medical System · Baltimore, MD
Photo of Baltimore  1Photo of Baltimore  2Photo of Baltimore  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Neoplasms, Brain
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old and willing to give informed consent.
Subjects with a suspected glioblastoma tumor on pre-operative brain imaging scans are eligible for enrollment in this study.
You have a score of 70 or more on the Karnofsky Performance Score.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.